Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208286 | 0.91 | GPR52 (0.65) | GPR52HTR2B | |
| SCHEMBL3212814 | 0.88 | GPR52 (1.00) | GPR52HTR2B | |
| SCHEMBL1852125 | 0.87 | GPR52 (0.59) | GPR52HTR2B | |
| SCHEMBL1852096 | 0.87 | GPR52 (0.59) | GPR52HTR2B | |
| SCHEMBL1852420 | 0.83 | GPR52 (0.55) | GPR52HTR2B | |
| SCHEMBL1856629 | 0.82 | GPR52 (0.56) | GPR52HTR2B | |
| SCHEMBL1850359 | 0.81 | GPR52 (0.78) | GPR52HTR2B | |
| SCHEMBL1851003 | 0.80 | GPR52 (0.83) | GPR52 | |
| SCHEMBL1852041 | 0.79 | GPR52 (0.82) | GPR52 | |
| SCHEMBL1849011 | 0.79 | GPR52 (0.82) | GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885HTR2B 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.